416 related articles for article (PubMed ID: 21280009)
1. Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series.
Nigrovic PA; Mannion M; Prince FH; Zeft A; Rabinovich CE; van Rossum MA; Cortis E; Pardeo M; Miettunen PM; Janow G; Birmingham J; Eggebeen A; Janssen E; Shulman AI; Son MB; Hong S; Jones K; Ilowite NT; Cron RQ; Higgins GC
Arthritis Rheum; 2011 Feb; 63(2):545-55. PubMed ID: 21280009
[TBL] [Abstract][Full Text] [Related]
2. Anakinra for systemic juvenile arthritis: the Rocky Mountain experience.
Zeft A; Hollister R; LaFleur B; Sampath P; Soep J; McNally B; Kunkel G; Schlesinger M; Bohnsack J
J Clin Rheumatol; 2009 Jun; 15(4):161-4. PubMed ID: 19363453
[TBL] [Abstract][Full Text] [Related]
3. Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France.
Lequerré T; Quartier P; Rosellini D; Alaoui F; De Bandt M; Mejjad O; Kone-Paut I; Michel M; Dernis E; Khellaf M; Limal N; Job-Deslandre C; Fautrel B; Le Loët X; Sibilia J; ;
Ann Rheum Dis; 2008 Mar; 67(3):302-8. PubMed ID: 17947302
[TBL] [Abstract][Full Text] [Related]
4. Anakinra treatment for systemic onset juvenile idiopathic arthritis (SOJIA).
Ohlsson V; Baildam E; Foster H; Jandial S; Pain C; Strike H; Ramanan AV
Rheumatology (Oxford); 2008 Apr; 47(4):555-6. PubMed ID: 18321945
[No Abstract] [Full Text] [Related]
5. The efficacy and safety of interleukin-1-receptor antagonist anakinra in the treatment of systemic juvenile idiopathic arthritis.
Swart JF; Barug D; Möhlmann M; Wulffraat NM
Expert Opin Biol Ther; 2010 Dec; 10(12):1743-52. PubMed ID: 20979564
[TBL] [Abstract][Full Text] [Related]
6. Combination therapy of abatacept and anakinra in children with refractory systemic juvenile idiopathic arthritis: a retrospective case series.
Record JL; Beukelman T; Cron RQ
J Rheumatol; 2011 Jan; 38(1):180-1. PubMed ID: 21196588
[No Abstract] [Full Text] [Related]
7. Anakinra treatment for systemic juvenile idiopathic arthritis and adult onset Still disease.
Woo P
Ann Rheum Dis; 2008 Mar; 67(3):281-2. PubMed ID: 18292104
[No Abstract] [Full Text] [Related]
8. Effective use of the recombinant interleukin 1 receptor antagonist anakinra in therapy resistant systemic onset juvenile rheumatoid arthritis.
Verbsky JW; White AJ
J Rheumatol; 2004 Oct; 31(10):2071-5. PubMed ID: 15468378
[TBL] [Abstract][Full Text] [Related]
9. Juvenile idiopathic arthritis presenting with prolonged fever.
Yeh TL; Huang FY; Shyur SD; Chen TL; Lee CS; Huang DT
J Microbiol Immunol Infect; 2010 Jun; 43(3):169-74. PubMed ID: 21291842
[TBL] [Abstract][Full Text] [Related]
10. Concomitant medication use in a large, international, multicenter, placebo controlled trial of anakinra, a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis.
Tesser J; Fleischmann R; Dore R; Bennett R; Solinger A; Joh T; Modafferi D; Schechtman J;
J Rheumatol; 2004 Apr; 31(4):649-54. PubMed ID: 15088288
[TBL] [Abstract][Full Text] [Related]
11. Functional and prognostic relevance of the -173 polymorphism of the macrophage migration inhibitory factor gene in systemic-onset juvenile idiopathic arthritis.
De Benedetti F; Meazza C; Vivarelli M; Rossi F; Pistorio A; Lamb R; Lunt M; Thomson W; Ravelli A; Donn R; Martini A;
Arthritis Rheum; 2003 May; 48(5):1398-407. PubMed ID: 12746913
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of repeated intravenous infusions of an anti-tumor necrosis factor alpha monoclonal antibody, infliximab, in persistently active, refractory juvenile idiopathic arthritis: results of an open-label prospective study.
Gerloni V; Pontikaki I; Gattinara M; Desiati F; Lupi E; Lurati A; Salmaso A; Fantini F
Arthritis Rheum; 2005 Feb; 52(2):548-53. PubMed ID: 15693004
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type.
Quartier P; Taupin P; Bourdeaut F; Lemelle I; Pillet P; Bost M; Sibilia J; Koné-Paut I; Gandon-Laloum S; LeBideau M; Bader-Meunier B; Mouy R; Debré M; Landais P; Prieur AM
Arthritis Rheum; 2003 Apr; 48(4):1093-101. PubMed ID: 12687553
[TBL] [Abstract][Full Text] [Related]
14. [New treatments for idiopathic juvenile arthritis].
Bader-Meunier B; Quartier P
Arch Pediatr; 2009 Dec; 16(12):1607-11. PubMed ID: 19896351
[TBL] [Abstract][Full Text] [Related]
15. Anakinra therapy in a child with systemic-onset juvenile rheumatoid arthritis after human herpesvirus 6 encephalitis.
Mirkinson LJ; Nagle D; Kadom N; Jones OY
J Clin Rheumatol; 2006 Apr; 12(2):83-6. PubMed ID: 16601542
[TBL] [Abstract][Full Text] [Related]
16. Rituximab therapy produced rapid and sustained clinical improvement in a patient with systemic onset juvenile idiopathic arthritis refractory to TNF alpha antagonists.
Feito JG; Pereda CA
J Clin Rheumatol; 2009 Oct; 15(7):363-5. PubMed ID: 20009975
[TBL] [Abstract][Full Text] [Related]
17. Randomized, placebo-controlled, crossover trial of low-dose oral methotrexate in children with extended oligoarticular or systemic arthritis.
Woo P; Southwood TR; Prieur AM; Doré CJ; Grainger J; David J; Ryder C; Hasson N; Hall A; Lemelle I
Arthritis Rheum; 2000 Aug; 43(8):1849-57. PubMed ID: 10943876
[TBL] [Abstract][Full Text] [Related]
18. A case of macrophage activation syndrome successfully treated with anakinra.
Kelly A; Ramanan AV
Nat Clin Pract Rheumatol; 2008 Nov; 4(11):615-20. PubMed ID: 18825135
[TBL] [Abstract][Full Text] [Related]
19. Interleukin-1 blockade by anakinra improves clinical symptoms in patients with neonatal-onset multisystem inflammatory disease.
Lovell DJ; Bowyer SL; Solinger AM
Arthritis Rheum; 2005 Apr; 52(4):1283-6. PubMed ID: 15818707
[TBL] [Abstract][Full Text] [Related]
20. Juvenile idiopathic arthritis--current and future therapies.
Kahn P
Bull NYU Hosp Jt Dis; 2009; 67(3):291-302. PubMed ID: 19852753
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
